Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 11/301% below fair value
$2.07+0.02 (+0.98%)
Close on Nov 13, 2026Market cap $122.93MP/E 29.6Yield –
Foghorn Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Foghorn Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$83.62M. For fiscal 2025 it was -$86.10M. The highest annual figure on record is $193.61M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$86.10M | – |
| FY2024 | Dec 31, 2024 | -$100.41M | – |
| FY2023 | Dec 31, 2023 | -$118.11M | -161.0% |
| FY2022 | Dec 31, 2022 | $193.61M | – |
| FY2021 | Dec 31, 2021 | -$50.25M | – |
| FY2020 | Dec 31, 2020 | -$31.29M | – |
| FY2019 | Dec 31, 2019 | -$46.34M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$18.24M | – |
| Q2 FY2026 | Jun 30, 2026 | -$17.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.21M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.18M | -111.5% |
| Q4 FY2022 | Dec 31, 2022 | -$28.92M | -343.4% |
| Q3 FY2022 | Sep 30, 2022 | -$19.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.01M | – |
| Q1 FY2022 | Mar 31, 2022 | $271.53M | – |
| Q4 FY2021 | Dec 31, 2021 | $11.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.50M | -852.1% |
| Q2 FY2021 | Jun 30, 2021 | -$18.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.66M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.60M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.76M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.18M | – |
See a number that looks wrong?